Construction and validation of a prognostic model of lncRNAs associated with RNA methylation in lung adenocarcinoma

被引:0
作者
Zhang, Liren [1 ]
Yang, Lei [2 ]
Chen, Xiaobo [3 ]
Huang, Qiubo [3 ]
Ouyang, Zhiqiang [4 ]
Wang, Ran [5 ]
Xiang, Bingquan [6 ]
Lu, Hong [1 ]
Ren, Wenjun [1 ,7 ]
Wang, Ping [1 ]
机构
[1] Kunming Med Univ, Affiliated Hosp 2, Dept Thorac Surg, 374 Dianmian St, Kunming 650101, Peoples R China
[2] Kunming Med Univ, Peoples Hosp Kunming 1, Calmette Hosp, Dept Tradit Chinese Med Rehabil Med, Kunming, Peoples R China
[3] Kunming Med Univ, Yunnan Canc Hosp, Yunnan Canc Ctr, Affiliated Hosp 3,Dept Thorac Surg 1, Kunming, Peoples R China
[4] Kunming Med Univ, Kunming Yanan Hosp, Yanan Hosp, Dept Radiol, Kunming, Peoples R China
[5] Univ Calif Irvine, Dept Epidemiol & Biostat, Irvine, CA USA
[6] Kunming Med Univ, Yunnan Canc Hosp, Affiliated Hosp 3, Yunnan Canc Ctr ,Dept Intens Care Unit, Kunming, Peoples R China
[7] Kunming Univ Sci & Technol, Peoples Hosp Yunnan Prov 1, Affiliated Hosp, Dept Cardiovasc Surg, 157 Jinbi Rd, Kunming 650118, Peoples R China
关键词
Long non-coding RNAs (lncRNAs); RNA methylation regulators; prognostic model; immunotherapy response; PROGRESSION; CONTRIBUTES; PROLIFERATION; CELLS;
D O I
10.21037/tcr-24-1085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Lung adenocarcinoma (LUAD) is a common type of lung cancer and one of the leading causes of cancer death worldwide. Long non-coding RNAs (lncRNAs) play a crucial role in tumors. The purpose of this study was to explore the expression of lncRNAs associated with RNA methylation modification and their prognostic value in LUAD. Methods: The RNA sequencing and clinical data were downloaded from The Cancer Genome Atlas dataset, and the messenger RNA and lncRNAs were annotated by Ensemble. The lncRNAs related to RNA methylation regulators (RMlncRNAs) were filtered by Pearson correlation analysis between differentially expressed lncRNAs and RNA methylation regulators. Univariate Cox regression analysis, multivariate Cox regression analysis, and least absolute shrinkage and selection operator regression analysis were used to construct a prognostic model. The receiver operating characteristic curve (ROC) was plotted to validate the predictive value of the prognostic model. Then, tumor mutational burden (TMB) and microsatellite instability were used to compare the immunotherapy response. Finally, to perform a drug sensitivity analysis, the half-maximal inhibitory concentration (IC50) of targeted drugs was calculated using pRRophetic package. Results: In total, 18 RMlncRNAs associated with the prognosis of LUAD patients were identified. Then, six feature lncRNAs (NFYC-AS1, OGFRP1, MIR4435-2HG, TDRKH-AS1, DANCR, and TMPO-AS1) were used to construct a prognostic model. The ROC curves for training, testing, and validation sets showed that the prognosis model was effective. The subindex based on the prognostic model had a high correlation with TMB. The high-risk group might be subject to greater immune resistance according to the comparison of Tumor Immune Dysfunction and Exclusion scores. Finally, the IC50 of 11 drugs had differences between high- and low-risk group, and only three of the drug's target genes (ERBB4, CASP8, and CD86) were differentially expressed. Conclusions: In conclusion, a prognostic model based on six feature lncRNAs (NFYC-AS1, OGFRP1, MIR4435-2HG, TDRKH-AS1, DANCR, and TMPO-AS1) was constructed by bioinformatics analysis, which might provide a new insight into the evaluation and treatment of LUAD.
引用
收藏
页码:761 / 777
页数:21
相关论文
共 64 条
[1]   The role of m6A RNA methylation in cancer metabolism [J].
An, Yuanyuan ;
Duan, Hua .
MOLECULAR CANCER, 2022, 21 (01)
[2]  
Brunson Jason Cory, 2020, Journal of open source software, V5, DOI 10.21105/joss.02017
[3]   Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J].
Chalmers, Zachary R. ;
Connelly, Caitlin F. ;
Fabrizio, David ;
Gay, Laurie ;
Ali, Siraj M. ;
Ennis, Riley ;
Schrock, Alexa ;
Campbell, Brittany ;
Shlien, Adam ;
Chmielecki, Juliann ;
Huang, Franklin ;
He, Yuting ;
Sun, James ;
Tabori, Uri ;
Kennedy, Mark ;
Lieber, Daniel S. ;
Roels, Steven ;
White, Jared ;
Otto, Geoffrey A. ;
Ross, Jeffrey S. ;
Garraway, Levi ;
Miller, Vincent A. ;
Stephens, Phillip J. ;
Frampton, Garrett M. .
GENOME MEDICINE, 2017, 9
[4]   Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer [J].
Chen, Dung-Tsa ;
Chan, Wenyaw ;
Thompson, Zachary J. ;
Thapa, Ram ;
Beg, Amer A. ;
Saltos, Andreas N. ;
Chiappori, Alberto A. ;
Gray, Jhanelle E. ;
Haura, Eric B. ;
Rose, Trevor A. ;
Creelan, Ben .
PLOS ONE, 2021, 16 (07)
[5]   RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2 [J].
Chen, Mengnuo ;
Wei, Lai ;
Law, Cheuk-Ting ;
Tsang, Felice Ho-Ching ;
Shen, Jialing ;
Cheng, Carol Lai-Hung ;
Tsang, Long-Hin ;
Ho, Daniel Wai-Hung ;
Chiu, David Kung-Chun ;
Lee, Joyce Man-Fong ;
Wong, Carmen Chak-Lui ;
Ng, Irene Oi-Lin ;
Wong, Chun-Ming .
HEPATOLOGY, 2018, 67 (06) :2254-2270
[6]   Long noncoding RNA lnc-H2AFV-1 promotes cell growth by regulating aberrant m6A RNA modification in head and neck squamous cell carcinoma [J].
Chen, Xi ;
Liu, Yunxia ;
Sun, Dongyuan ;
Sun, Rongqi ;
Wang, Xiaoxiao ;
Li, Minmin ;
Song, Ning ;
Ying, Jicheng ;
Guo, Tao ;
Jiang, Yingying .
CANCER SCIENCE, 2022, 113 (06) :2071-2084
[7]   TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data [J].
Colaprico, Antonio ;
Silva, Tiago C. ;
Olsen, Catharina ;
Garofano, Luciano ;
Cava, Claudia ;
Garolini, Davide ;
Sabedot, Thais S. ;
Malta, Tathiane M. ;
Pagnotta, Stefano M. ;
Castiglioni, Isabella ;
Ceccarelli, Michele ;
Bontempi, Gianluca ;
Noushmehr, Houtan .
NUCLEIC ACIDS RESEARCH, 2016, 44 (08) :e71
[8]   Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations [J].
Dantoing, Edouard ;
Piton, Nicolas ;
Salaun, Mathieu ;
Thiberville, Luc ;
Guisier, Florian .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
[9]   LncRNA TDRKH-AS1 promotes breast cancer progression via the miR-134-5p/CREB1 axis [J].
Ding, Yuqin ;
Huang, Yuting ;
Zhang, Fanrong ;
Gong, Lijie ;
Liang, Chenlu ;
Ding, Kaijing ;
He, Xiangming ;
Ding, Xiaowen ;
Chen, Yiding .
JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
[10]   LncRNA OGFRP1 promotes angiogenesis and epithelial-mesenchymal transition in colorectal cancer cells through miR-423-5p/CTCF axis [J].
Dong, Hongyu ;
Liu, Qi ;
Chen, Chaowu ;
Lu, Tailiang ;
Xu, Kaiwu .
IMMUNOBIOLOGY, 2022, 227 (02)